Cell Therapy News Volume 24.33 | Oct 23 2023

    0
    14








    2023-10-23 | CTN 24.33


    Cell Therapy News by STEMCELL Technologies
    Vol. 24.33 – 23 October, 2023
    TOP STORY

    KRAS G12V Neoantigen Specific T Cell Receptor for Adoptive T Cell Therapy against Tumors

    Scientists identified two T cell receptors (TCRs) specific for the 9-mer KRAS-G12V mutant neoantigen in the context of HLA-A*11:01. The TCR-T cells were constructed and displayed cytokine secretion and cytotoxicity upon co-culturing with varied tumor cells expressing the KRAS-G12V mutation.
    [Nature Communications]

    Full Article
    Cell Preparation For Crossmatch Assays
    PUBLICATIONSRanked by the impact factor of the journal

    Repair of Osteochondral Defects: Efficacy of a Tissue-Engineered Hybrid Implant Containing Both Human MSC and Human iPSC-Cartilaginous Particles

    Human iPSC-cartilaginous particles wrapped with tissue engineered constructs containing human mesenchymal stem cells attained secure defect filling with good integration to adjacent tissue in a rat osteochondral injury model.
    [NPJ Regenerative Medicine]

    Full Article

    Ex Vivo Pleural Effusion Cultures to Study Chimeric Antigen Receptor T Cell Cytotoxicity in an Immunocompetent Environment

    Investigators described an ex vivo pleural effusion culture assay, using malignant pleural-effusion-derived soluble and cellular factors that differentially affected the cytotoxicity of CAR T cells.
    [Cell Reports Methods]

    Full ArticleGraphical Abstract

    The HIFIA/LINC02913/IGF1R Axis Promotes the Cell Function of Adipose-Derived Mesenchymal Stem Cells under Hypoxia via Activating the PI3K/AKT Pathway

    The microarray dataset GSE12884 was analyzed to identify the differentially expressed lncRNAs in adipose-derived mesenchymal stem cells under normoxia and hypoxia. The expression of the key genes was detected using qRT-PCR, western blot assay, and immunofluorescence staining.
    [Journal Of Translational Medicine]

    Full Article

    Free Interleukin-18 Is Elevated in CD22 CAR T Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Toxicities

    After a comprehensive clinical characterization and cytokine profiling of patients enrolled in a Phase I clinical trial evaluating CD22 CAR T cells for B cell malignancies, investigators further analyzed samples from 10 patients with cytokine release syndrome for total IL-18, free IL-18, and IL-18BP.
    [Blood Advances]

    Full Article

    Translational Development of a Novel BAFF-R CAR-T Therapy Targeting B Cell Lymphoid Malignancies

    The authors presented the development of a novel CAR-T cell therapy targeting B-cell activating factor receptor, a key regulator of B-cell proliferation and maturation. A new monoclonal antibody against BAFF-R was generated from a hybridoma clone and used to create a novel MC10029 CAR construct.
    [Cancer Immunology Immunotherapy]

    AbstractGraphical Abstract

    Lipid Nanoparticles (LNPs) Outperform Electroporation in mRNA-Based CAR T Cell Engineering

    Lipid nanoparticles were examined for ex vivo CAR-mRNA delivery and compared to electroporation (EP). LNP-CAR T cells showed a significantly prolonged efficacy in vitro in comparison to EP-CAR T cells as a result of extended CAR-mRNA persistence and CAR expression.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractFull ArticleGraphical Abstract

    The Salvage Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma

    To clarify the role of allogeneic hematopoietic stem-cell transplantation (HSCT) in the CAR T cell therapy era, researchers analyzed the clinical characteristics and outcomes of 52 patients treated with allo-HSCT with relapsed/refractory diffuse large B cell lymphoma.
    [Scientific Reports]

    Full Article

    A Multi-Cohort Phase Ib Trial of Rituximab in Combination with Immunotherapy Doublets in Relapsed/Refractory Follicular Lymphoma

    Investigators conducted a Phase Ib trial testing time-limited therapy with different immunotherapy doublets targeting 4-1BB, OX-40, and PD-L1 in combination with rituximab among patients with relapsed/refractory grade 1–3A follicular lymphoma.
    [Annals Of Hematology]

    Abstract
    Five tips for returning to the lab after time off
    REVIEWS

    Synthetic Transcription Factor Engineering for Cell and Gene Therapy

    Recent advances in human-derived DNA-binding domains, and transcriptional activation domains paired with novel control modules responsive to clinically approved small molecules, have poised the synthetic transcription factorsF field to overcome hurdles.
    [Trends In Biotechnology]

    Abstract

    Mind the GAP: RASA2 and RASA3 GTPase-Activating Proteins As Gatekeepers of T Cell Activation and Adhesion

    Although many studies have helped to elucidate the signaling intermediates that mediate T cell activation, the molecules and pathways that keep naive T cells in check are less understood.
    [Trends in Immunology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Mass General Brigham Gene and Cell Therapy Institute Names First Winners of its Spark Grant Series

    The Mass General Brigham Gene and Cell Therapy Institute conducting clinical trials and developing FDA-approved treatments, announced the six winners of its first annual Spark Grant program.
    [Mass General Brigham]

    Press Release

    How to Pay for Million-Dollar Cures

    Patients describe a distinct before-and-after from gene therapy, but it’s less a lightning bolt than a slow dawning that begins by waking up one morning and realizing that their pain is gone.
    [Bloomberg]

    Editorial
    FEATURED EVENT

    Single Cell View 3D Genome Architecture

    November 26 – 29, 2023
    Buxted Park, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Immune Cells in Blood Diseases and GvHD

    Baylor College of Medicine – Houston, Texas, United States

    Doctoral Positions – Biomedical Research

    Berlin Institute of Health at Charit̩ РBerlin, Germany

    Faculty Position – Regenerative Medicine and Cell Biology

    Medical University of South Carolina – Charleston, South Carolina, United States

    Postdoctoral Position – Stem Cell Manufacturing

    Technical University of Denmark – Copenhagen, Denmark

    Staff Scientist – GMP for Stem Cell Therapies

    City of Hope – Duarte, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter